-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2022 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$19.2M, a 33.4% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2022 was -$76.4M, a 18.6% decline from 2021.
- Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2021 was -$64.4M, a 391% decline from 2020.
- Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2020 was -$13.1M, a 41.6% increase from 2019.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)